Neurogene announces registrational trial design for Embolden study of NGN-401

Neurogene (NGNE) “announced details of Embolden, the Company’s registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older. The Company has written agreement from the U.S. Food and Drug Administration on key aspects of the registrational trial’s design.”